# PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

> **NCT05573893** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 800 (estimated)

## Conditions studied

- Breast Neoplasms
- Breast Cancer
- Neoplasm Metastasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05573893
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-12
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05573893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05573893, "PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05573893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*